What is the dosing regimen, monitoring plan, contraindications, and common adverse effects of ribociclib for hormone‑receptor‑positive, HER2‑negative advanced or metastatic breast cancer?

Ribociclib for HR+/HER2- Advanced or Metastatic Breast Cancer

Ribociclib 600 mg once daily for 21 days followed by 7 days off (3-weeks-on/1-week-off schedule) in combination with an aromatase inhibitor or fulvestrant is the standard dosing regimen for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. 1

Dosing Regimen

• Standard dose: 600 mg orally once daily for 21 consecutive days, followed by 7 days off (28-day cycle) 1
• Dose reductions:
  • First reduction: 400 mg daily
  • Second reduction: 200 mg daily
  • Discontinue if unable to tolerate 200 mg 1

Combination Partners

First-line therapy:

• Postmenopausal women: Ribociclib + aromatase inhibitor (letrozole 2.5 mg daily or anastrozole) 2
• Premenopausal women: Ribociclib + aromatase inhibitor + goserelin (ovarian suppression) 2, 3
• The MONALEESA-7 trial demonstrated median PFS of 24 months versus 13 months with placebo, and importantly showed overall survival benefit at 3.5 years (70% vs 46%) 2

Second-line therapy (after progression on prior endocrine therapy):

• Ribociclib + fulvestrant 500 mg (with ovarian suppression in premenopausal women) 4

Monitoring Plan

Baseline Assessment

• Complete blood count with differential 1
• Comprehensive metabolic panel including liver function tests (AST, ALT, bilirubin) 2, 1
• ECG to assess QTc interval 1
• Pregnancy test in women of reproductive potential 1

Ongoing Monitoring

Hematologic monitoring:

• CBC on Day 1 and Day 15 of the first 2 cycles 5
• CBC on Day 1 of each subsequent cycle 5
• More frequent monitoring if Grade 3/4 neutropenia develops 1

Hepatic monitoring:

• Liver function tests every 2 weeks for the first 2 cycles 2, 1
• Then at the beginning of each subsequent 4 cycles 1
• Then as clinically indicated 1

Cardiac monitoring:

• ECG at baseline, Day 14 of first cycle, beginning of second cycle 1
• Repeat ECG as clinically indicated, particularly if QTc >480 msec 1

Contraindications

Based on the FDA label and clinical evidence 1:

• No absolute contraindications listed in the prescribing information
• Use extreme caution in patients with baseline QTc >450 msec
• Avoid strong CYP3A inhibitors (increase ribociclib exposure) 1, 6
• Avoid strong CYP3A inducers (decrease ribociclib exposure) 1, 6

Common Adverse Effects

Most Frequent (>20% incidence)

Hematologic toxicity (most common):

• Neutropenia: Grade 3/4 in 59-63% of patients 2, 7
• Leukopenia: Grade 3/4 in 21% of patients 2, 7
• Febrile neutropenia is rare (1-2%) 7
• Anemia: Grade 3/4 in 5.4% 2

Hepatotoxicity:

• Elevated ALT/AST: Grade 3/4 in 10.2% 2
• Monitor closely; may require dose reduction or corticosteroids in severe cases 8

QTc prolongation:

• Grade 3/4 QTc prolongation in 1.8-2% 2, 3
• Mean QTc increase of 22.97 msec at 600 mg dose 6

Gastrointestinal:

• Nausea, diarrhea, vomiting (generally Grade 1-2) 9

Dermatologic:

• Cutaneous reactions in 26.4% of patients 10
• Patterns include pruritus, erythematous rash, eczematous rash, vitiligo 10
• Most are Grade 1-2; Grade 3-4 rare (including rare TEN) 10
• Median onset 84 days; most improve with supportive care 10

Management of Key Toxicities

Neutropenia:

• Grade 3 (ANC 500-1000/mm³): Hold until recovery to Grade ≤2, resume at same dose 1
• Grade 4 (ANC <500/mm³): Hold until recovery to Grade ≤2, resume at next lower dose 1
• Recurrent Grade 3/4: Reduce dose 1

Hepatotoxicity:

• Grade 2 (ALT/AST >3-5× ULN): Hold until recovery to Grade ≤1, resume at same dose 1
• Grade 3 (ALT/AST >5-20× ULN): Hold until recovery to Grade ≤1, resume at reduced dose 1
• Grade 4 or recurrent Grade 3: Discontinue permanently 1
• Consider corticosteroids for severe, persistent hepatotoxicity despite drug cessation 8

QTc prolongation:

• QTc >480 msec: Hold until QTc <481 msec, resume at reduced dose 1
• QTc >500 msec: Discontinue permanently 1
• Critical caveat: Avoid concomitant tamoxifen due to additive QT prolongation risk 1

Clinical Pearls

• Real-world data shows dose reduction occurs in approximately 44% of patients, with permanent discontinuation in 13.2% due to adverse events 11
• Despite dose reductions, efficacy is maintained with median PFS of 18 months in real-world practice 11
• The 3-weeks-on/1-week-off schedule allows for hematologic recovery during the off-week 5
• Ribociclib inhibits CYP3A at 600 mg, requiring caution with CYP3A substrates 6
• Age, body weight, race, mild hepatic impairment, and mild-to-moderate renal impairment do not require dose adjustment 6